BD (Becton, Dickinson and Company) posted a 5.4% increase in Q3 revenue to $5.0 billion, driven by growth across its Medical Essentials, Connected Care, BioPharma Systems, and Interventional segments. Adjusted diluted EPS rose to $3.23, and cash from operations grew 33.3% year-to-date. The company updated its full-year guidance, expecting revenue growth at the high end of its range and raising the midpoint of adjusted EPS guidance, reflecting strong momentum from its focused MedTech strategy and ongoing innovation. BD also highlighted recent product launches and collaborations that support its growth trajectory.
Among four Dividend Aristocrats highlighted a year ago, AbbVie and Becton Dickinson outperformed the market with strong dividend growth and solid financials, while Procter & Gamble and Brown-Forman lagged in price but maintained reliable dividend pay...
Becton, Dickinson and Company (BD) reported strong Q3 fiscal 2026 results, surpassing analyst expectations with an EPS of $3.23 versus the estimated $3.14, and revenue of $4.98 billion beating the $4.89 billion forecast. Despite a year-over-year EPS ...
